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On imaging, speed, and the future of lymphocyte signaling
 
Alexander Tarakhovsky
 
During a recent roundtable discussion, we captured some personal
perspectives on the new insight that advanced imaging techniques promise to 
bring to the study of lymphocyte signaling. The experts present their views on 
the power of imaging, the problems that need to be overcome, and the 
potential of the technology.
 
Images of cells are perplexing. Geneti-
cally tinted by the jellyfish fluorescent
protein painter kit, cells of all colors
and shapes turn serious academic jour-
nals into modern art catalogues. After
decades of abstract thinking and fre-
quently fruitless interpretation of bands,
dots, and their graphic derivatives, the
attention of many scientists is now at-
tracted by the opportunity to see almost
everything in
 
 
 
“real” life. The increased
communication value of images is a
part of a rapidly evolving cultural ten-
dency demanding real-time event docu-
mentation. Nowhere could be more
remote from this problem than the
caught-in-time Certosa di Pontignano,
an old castle near Siena, Italy. Maybe
that is why we decided to organize a
roundtable discussion about imaging
during the 2004 EMBO workshop on
Lymphocyte Antigen Receptor and
Coreceptor Signaling held at this loca-
tion (1). We asked the experts to reflect
on the impact of imaging on a field that
has been dominated by biochemical
approaches. Our aim was to capture
some personal viewpoints on the real
and virtual power of imaging and the
new challenges the technology brings.
Can the traditional craft of cell manip-
ulation match the high speeds that can
now be visualized? What new reagents
are needed to allow us to take full ad-
vantage of imaging in the lymphocyte
signaling field? Should imaging data be
quantified (definitely, yes!) and if so
how? (See also the related Commen-
tary on page 501 of this issue [2].) At
the end, we asked the participants to
fantasize about how we might be using
imaging technology to study lymphocyte
signaling in the more distant future.
I regret that we could not present
all of the lively discussion, but we have
included comments and exchanges on
some of the key topics that were cov-
ered. We thank all the participants for
their willingness to share their insight
and opinions.
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POWER OF IMAGES
 
Mark M. Davis
 
: If you ask, “What’s
the value of imaging?” one important
thing is that it allows us to escape the
tyranny of population biochemistry.
We’ve been forced to indulge in the
fantasy that if you have a million cells
in a tube, and you hit them with some-
thing, that they’re all going to do ex-
actly the same thing at the same time.
However, we know that a lot of sto-
chastic processes are going on. If you
just grind the cells up at different time
points, you’re averaging over all those
processes. It’s only when you can see
an individual cell that you can see it
was stimulated, and then went on a
particular pathway. And there’s a level
of quantitation we’ve never seen with
biochemistry. We’re getting much more
precise answers to questions like the
amount of calcium that’s being released
during T cell activation. We can see
that one peptide gives you X amount of
calcium, and two give you 2X, and so
forth (3).
 
Lawrence E. Samelson
 
: With imag-
ing, it’s not just that you’re able to
overcome the heterogeneity of the cell
population; you’re able to overcome
the heterogeneity of the intracellular
molecular populations. Many of the
molecules that we tag and look at, in
terms of intracellular signaling proteins,
exist in different pools in the cell: some
are cytoplasmic, some are recruited to
the membrane, others are associated
with the cytoskeleton. It would be im-
possible to study these different popula-
tions without imaging the individual
cells and individual molecules.
 
Bernard Malissen
 
: We are also feel-
ing out the speed at which signaling
processes are working, and it’s very
fast. Neurobiologists have known that
for a very long time. We are just put-
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Glossary
 
FRET:
 
 
 
fluorescent resonance energy transfer
 
FRAP:
 
 
 
fluorescence recovery after photo-
bleaching
 
ZAP-70:
 
 
 
 
 
-associated protein of 70 KD; a 
pivotal molecule in membrane proximal 
T cell receptor signaling
 
Immune synapse:
 
 organized structure that 
forms at the interface of an antigen-presenting 
cell and antigen-specific T cell
 
Lipid rafts:
 
 cholesterol-rich plasma membrane 
microdomains that have been implicated in 
lymphocyte signaling
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ting our finger on the speed at which a
T cell is responding to an antigen. So
imaging gives you an idea of the time-
scale we should be thinking of.
 
Arthur Weiss
 
: I think that imaging in
real time is critical. But in addition,
FRAP technology allows us to see
things that we never imagined, in terms
of the turnover and the dynamics of
structures that we think are static. Be-
cause you see an immune synapse, you
think everything is just sitting there and
immobile with no turnover.
 
MMD
 
: There are a lot of technical
challenges involved in asking questions
of a detailed molecular nature, of mole-
cules that are within particular cells, at
particular times, and in particular places.
But it’s the future of understanding
how these cells work. There are huge
challenges in getting markers for events
inside the cell. But there are already
some that are specifically designed as
indicators of a particular kind of phos-
phorylation. We need many more of
those for all the different signals that
might be going on.
 
Rose Zamoyska
 
: Single molecule im-
aging is coming, and it’s not that far
off. That really is going to add another
dimension to the way we’re going to
be able to analyze signaling events.
 
IMAGING MEETS BIOCHEMISTRY 
AND GENETICS
 
Oreste Acuto
 
: Nobody would dis-
agree with all that has been said so far.
But we should never forget that bio-
chemistry gives us the fastest way to es-
tablish protein–protein interactions, and
the highest resolution.
 
BM
 
: Ultimately, genetics should allow
you to order a pathway without having
help of biophysics. If you have power-
ful genetics, like in the yeast, you can
do very nice ordering and epistatic anal-
yses of pathways, and you don’t need
imaging.
 
RZ
 
: One of the problems with bio-
chemistry is that you can never look at
the consequences of the signals, because
the cells are lysed. And one of the advan-
tages of imaging is that we’re developing
techniques where you’ll be able to look
at the differentiation consequences, down-
stream of particular signals.
 
Christopher C. Goodnow
 
: When-
ever I hear the biochemistry angle, I al-
ways think about Arthur Kornberg and
how proud he was of DNA polymer-
ase in the tube, until the geneticists
knocked it out in bacteria, and they
replicated just fine. It’s very hard to or-
der pathways and I think the triangula-
tion between biochemistry, genetics,
and imaging is going to be essential.
You need to know where things are in
the cell, and their kinetics and the dy-
namics, which is what the imaging tells
you. You need to know what could
happen, which is what the test tube ex-
periment tells you. And then the ge-
netics tells you
 
 
 
what is actually needed
for a given process. As a community,
we don’t put enough emphasis, in our
publication and referee processes, on
when the genetics and the biochemis-
try are disconnected. For example, we
have a ZAP-70 catalytic domain point
mutant mouse, which has a severe
problem with thymic positive selection
(unpublished data). The genetics is tell-
ing us that there is a real problem. But
when we look at tyrosine phosphor-
ylation and do old-fashioned calcium
analysis, we can’t see any problem. So
the biochemistry is disconnected from
the genetics. The question is if you did
high speed imaging, would we sud-
denly be able to connect the genetics
with the biochemistry?
 
Michael Reth
 
: The immune synapse
is a nice example of how difficult it can
be to correlate image analysis data with
the biochemical behavior of molecules
inside a cell. When the synapse was first
discovered, everybody thought that one
had finally found the molecular or-
ganization of signaling proteins at the
activated T cell antigen receptor. Yet
when people later on analyzed synapse
formation at different time points and
used antiphosphotyrosine antibodies (4),
it became clear that TCR signaling
happens much earlier than synapse for-
mation, and that the synapse may have
more to do with the secretion of cyto-
kines than with the initiation of the
TCR signal.
 
MMD
 
: Absolutely, when we first see
things we’re invariably going to misin-
terpret them. Seeing may be believing,
but it isn’t always understanding.
 
MR
 
: Another source of artifacts is the
use of GFP-tagged proteins to follow
the behavior of molecules in a living
cell. This is a powerful tool, but it is
important to first test whether the fu-
sion to GFP is not drastically changing
the localization or biochemical behav-
ior of the fusion proteins inside the
cell. Another problem is the use of flu-
orescent reagents to visualize structures
in living cells like lipid rafts. In this re-
spect, it was interesting to see that
when FITC-coupled cholera toxin was
used to detect raft structures it resulted
in raft aggregation (5). So you are cre-
ating what you want to observe.
 
“There’s still a bag of genetic tricks 
that hasn’t really been applied to
imaging but which could be used 
…photo-activatable GFP, for example, 
 
and temperature-sensitive mutations.”
 
QUANTITATING IMAGES
 
MR
 
: One problem we have to solve is
how to quantify our image analysis.
When I see a publication with a beauti-
ful picture of a cell showing the local-
ization of the GFP-tagged protein to a
particular membrane structure, I won-
der how representative this image is of
the behavior of these proteins in the cell
population. To overcome the bias gen-
erated by our eyes and our brain, we
need to apply computer programs for
image analysis which, similar to a FAC-
Scan, can quantify images and order
cells according to the image phenotype.
 
LES
 
: Many of these problems are
problems that all cell biologists have.
You look at a picture in a journal, and
you say, “How do I know this is repre-
sentative?” That gets into the question
of honesty, and ethics, and basically
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good science. But programs for quanti-
tation exist; you can track movement;
you can quantitate velocity; you can
quantitate dynamics. So a lot of what
we need is there.
 
Salvatore Valitutti
 
: It’s very possible
to quantitate morphology. It’s very
tough. Very time consuming. But it is
possible to ask authors for quantifica-
tion, or even to show the originals
from which the quantitation was made.
 
Alexander Tarakhovsky
 
: Do you
think that there is an absolute necessity
to introduce ways to quantify images?
 
SV
 
: I think it will be in the interests of
people doing morphology to somehow
enforce measurements of intensity, for
instance, at the immune synapse.
 
MMD
 
: The referees always ask us for
quantitation: what does the cell popu-
lation do? How many cells do this?
How many cells do that? On some oc-
casions, when the referees have been
skeptical about our interpretation of
the images, they ask for all the images,
and we send all the images on a CD. So
the vetting is actually easier than it used
to be, in the sense that you can trans-
mit vast amounts of information very
quickly, so that people can be sure that
you’re not being subjective. As to a
program that Bill Gates would sell us to
do this—fine, when it happens. But
there are many different questions you
can ask using imaging. I can imagine a
very simple kind of software being
good for some kinds of imaging analy-
sis, but completely useless for other
kinds.
 
Claire Hivroz
 
: One of the problems
that we have to face is that while these
new imaging techniques are really nice,
they are sources of artifacts, also. We
really need to do the analysis carefully.
Biologists are not physicists, and some-
times we don’t know how to analyze
the image, or we don’t know exactly
how to use the software. I think we
have to make great efforts to work with
physicists, to really understand what we
are doing because being sure, for ex-
ample, that what we are looking at by
FRET is really an interaction between
two proteins is not that easy.
 
ADVANCING THE TECHNOLOGY
 
MR
 
: By using GFP-tagged proteins we
can employ imaging to localize pro-
teins to certain subcellular structures,
but what is really lacking are more
techniques to not only measure the lo-
calization, but also the activity of a pro-
tein. Of course, we can measure the
intracellular increase of calcium by flu-
orescent dyes, but these dyes cannot be
localized to certain places inside the
cell. What we need are more GFP vari-
ants that change their fluorescence upon
modification, like calcium binding, phos-
phorylation, or oxidation. With such
techniques, you can then see in real
time, not only the localization of mole-
cules in the cell, but also at what time
point these proteins become active or
modified.
 
“As a community, we don’t put 
enough emphasis, in our publication 
and referee processes, on when the 
genetics and the biochemistry are
 
disconnected.”
 
Anjana Rao
 
: I’m dealing with a pro-
gram of transcriptional regulation that
is sensitive to very low intracellular cal-
cium levels—lower than can be mea-
sured reliably by the available technol-
ogy. So I think, in the case of calcium
imaging, we’re clearly going to need
some new technology in the picture.
 
MMD
 
: There’s still a bag of genetic
tricks that hasn’t really been applied to
imaging but which could be used.
There is development of photo-acti-
vatable GFP, for example, and temper-
ature-sensitive mutations. So it might
be possible to give cells a burst of a la-
ser, for example, to alter the function
of molecules that you had modified.
 
AT
 
: Do you think that one can manip-
ulate structures such as the immune
synapse?
 
CCG
 
: The strength of genetics is in
the specificity of the dissection. But the
limitation is that you just have no tem-
poral control or spatial control. So, in
that respect, it’s a very limited tool.
The ideal scenario would be to replace
genetics with pharmacology. To have
small molecules that you can add in to
inhibit signaling pathways, which are as
specific as genetic manipulations. But,
of course, where we get into trouble is
in knowing how specific a compound
is. This is where the neurobiologists,
and the cardiologists, have it over us as
immunologists. They’ve got a panoply
of quite specific agents to dissect pro-
cesses such as cardiac contractility.
 
AT
 
: Do you think that genetic manip-
ulation could allow conditional protein
inactivation at a given time point?
 
CCG
 
: Inactivation has to happen very
fast. The only thing would be some
adaptation of photo-inactivatable or
temperature-sensitive alleles, which as
Mark [MMD] has pointed out, could
allow you to eliminate a wild-type sig-
naling protein both rapidly and in a
specific region of a cell.
 
MR
 
: New in vivo imaging studies can
follow the dynamic behavior of single
lymphocytes in the tissue of a living
mouse. This, in combination with ge-
netics, will allow us to understand better
the dynamics of cellular interactions in-
side the immune system. To follow the
behavior and activity of single molecules
inside a lymphocyte is much more de-
manding technically, as these are rapid
and very dynamic processes. One needs
machines with a very fast kinetic image
acquisition if one wants to follow these
events in real time. Furthermore, if one
wants to track single fluorescent mole-
cules, one has to use a lot of laser light to
detect them, and this could be another
potential source of artifacts. Laser light
not only results in photobleaching, but
can also generate reactive oxygen spe-
cies. As many signaling processes inside
the cell are highly sensitive to redox
changes, it is possible that shining a lot
of laser light on the molecules can
change their regulation and behavior.
 
AW
 
: One thing I want to stress again is
quantitation. And maybe genetics can
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help there. Chris [CCG] talked about a
point mutation which doesn’t show any
biochemical difference. We might not
be able to validate that our GFP con-
structs are behaving normally using
simple overexpression systems. I would
argue that maybe we can use genetic
approaches to test the constructs we use
to validate the fact that we’re expressing
the right amount of protein, in the right
place, at the right time, and that those
proteins are regulated properly. Maybe
we can harness the power of genetics
for proper expression—right place, right
time, as well as right level.
 
AR
 
: In terms of technology develop-
ment, there are two things that I would
focus on. Microinjection of mutant pro-
teins into cells that don’t have that pro-
tein would be a very good thing to
develop. The protein can be tagged
in various ways, with small fluorescent
probes for instance. And second, I think
electron microscopy will be important.
Think about the work that Gunther
Blobel did, for instance, with the nuclear
pore and with nuclear import and ex-
port. He had the biochemistry. He had
all the different subunits. And then he
used EM to localize them in the basket
of the nuclear pore. The stable immune
synapse is such a structure that could
benefit very greatly from EM analysis.
 
IMAGINING THE FUTURE OF IMAGING
 
AT
 
: Now I want you to dream.
 
AR
 
: To dream?
 
AT
 
: Yes. So, without discussing limi-
tations, tell me how do you think in
ten years your dreams will be fulfilled?
[Laughter]
 
MR
 
: My dream is a very powerful
computer program that is able to gen-
erate a virtual cell where we can test
our hypothesis of protein signals inside
cells. Using the primary sequence data,
this program should be able to generate
the tertiary structure of the protein not
only in its frozen (crystal) stage, but
also its normal dynamic stage in solu-
tion. With such a program, one could
follow the conformational changes of
proteins and better understand the dy-
namic processes of protein–protein in-
teractions during cell signaling. So that
is a dream, but I think one has to wait
quite a while for such a program.
 
MMD
 
: I don’t think a computer
would be able to know how evolution
built a cell. So I think that dream is go-
ing to come to a bad end. But in my
childhood, there was a movie called
“Fantastic Voyage,” where there was a
tiny, little ship that was built, and min-
iaturized humans were in it. They
cruised around the bloodstream, and
they looked at the lymphocytes and
other things from this point of view. So
a good dream would be one where you
miniaturize the ship even more, such
that you could go into a cell, through
a channel or something, and cruise
around the cell and watch different bits
of the machinery moving up and down,
or doing whatever it does.
 
AR
 
: I think you’d find what Schrödinger
predicted in 1944 (6). You’d find proba-
bilistic movements. I think the whole
workings of the cell are governed by
probability and stochastic movements that,
in turn, are governed by the affinity of
interaction. My dream would be to apply
the imaging techniques we’re talking
about at the membrane, today, to find
out what happens in the nucleus.
 
LES
 
: Mine is another cautionary tale
from early twentieth-century physics,
and that is the Heisenberg Uncertainty
Principle. We have to watch out for
what we do to these systems. Certainly
by manipulating systems we create arti-
facts. So that’s a nightmare.
[Laughter]
 
OA
 
: My ultimate dream is that we
abolish competition. We create a big
center and attack very fundamental, ba-
sic paradigms in a few systems. It is not
strictly necessary to know everything,
with everybody working in their own
little corner. Why not combine genet-
ics, imaging, and biochemistry in a
dedicated center where scientists can
perform challenging experiments, like
physicists do? That’s a dream. That’s
something that I think should work.
[Applause]
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